Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$94.69M

FY 2025 · Annual

Investing Cash Flow

-$247.01M

FY 2025 · Annual

Financing Cash Flow

$360.77M

FY 2025 · Annual

+1318.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.96M)(51.51M)(75.52M)(69.63M)(127.41M)
Depreciation & Amortization15K68K96K282K26K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(6.51M)7.76M9.8M(11.17M)(8.2M)
Accounts Receivables00000
Inventory00000
Accounts Payables609K1.37M(164K)(2.17M)361K
Other Working Capital(7.12M)6.39M9.96M(9M)(8.56M)
Other Non-Cash Items2.06M4.57M8.85M9.32M40.89M
Operating Cash Flow(27.4M)(39.12M)(56.78M)(71.2M)(94.69M)
Capital Expenditures(181K)(195K)(142K)0(196K)
Acquisitions (Net)00000
Purchases of Investments(113.25M)(147.62M)(123.98M)(19.68M)(261.19M)
Sales of Investments0154.74M136M75.71M14.42M
Other Investing Activities0000(31K)
Investing Cash Flow(113.43M)6.93M11.88M56.03M(247.01M)
Debt Repayment00000
Common Stock Issued190.46M396K46M25.43M360.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000156K
Financing Cash Flow190.46M396K46M25.43M360.77M
Effect of Forex Changes0000(52.82M)
Net Change in Cash49.62M(31.8M)1.09M10.26M54.69M
Free Cash Flow(27.58M)(39.32M)(56.92M)(71.2M)(94.89M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$127.4M
+ D&A$26.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$8.2M
+ Other Non-Cash$40.9M
= Operating Cash Flow-$94.7M
- Capex-$196.0K
= Free Cash Flow-$94.9M

Analysis

FY2025 free cash flow is -$94.9M. FCF conversion is 74.5% of net income. Operating cash flow was -$94.7M, with capex of -$196.0K. The largest bridge item is Other Non-Cash at $40.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 13, 2026
10-QQuarterly reportNov 13, 2026
SC 13GSC 13G filingOct 28, 2026
SC 13GSC 13G filingOct 27, 2026
424B5424B5 filingJun 3, 2026

Does JBIO generate free cash flow?

Jade Biosciences, Inc. (JBIO) generated -$94.89M of free cash flow in fiscal 2025.

How much operating cash flow does JBIO produce?

Operating cash flow was -$94.69M, before capital expenditures of $196,000.00.